These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16518829)

  • 1. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
    Tsunetsugu-Yokota Y; Ohnishi K; Takemori T
    Rev Med Virol; 2006; 16(2):117-31. PubMed ID: 16518829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS.
    Zhang MY; Choudhry V; Xiao X; Dimitrov DS
    Curr Opin Mol Ther; 2005 Apr; 7(2):151-6. PubMed ID: 15844623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The possible of immunotherapy for COVID-19: A systematic review.
    AminJafari A; Ghasemi S
    Int Immunopharmacol; 2020 Jun; 83():106455. PubMed ID: 32272396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
    Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
    Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
    See RH; Petric M; Lawrence DJ; Mok CPY; Rowe T; Zitzow LA; Karunakaran KP; Voss TG; Brunham RC; Gauldie J; Finlay BB; Roper RL
    J Gen Virol; 2008 Sep; 89(Pt 9):2136-2146. PubMed ID: 18753223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
    Lin JT; Zhang JS; Su N; Xu JG; Wang N; Chen JT; Chen X; Liu YX; Gao H; Jia YP; Liu Y; Sun RH; Wang X; Yu DZ; Hai R; Gao Q; Ning Y; Wang HX; Li MC; Kan B; Dong GM; An Q; Wang YQ; Han J; Qin C; Yin WD; Dongs XP
    Antivir Ther; 2007; 12(7):1107-13. PubMed ID: 18018769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.
    Miyoshi-Akiyama T; Ishida I; Fukushi M; Yamaguchi K; Matsuoka Y; Ishihara T; Tsukahara M; Hatakeyama S; Itoh N; Morisawa A; Yoshinaka Y; Yamamoto N; Lianfeng Z; Chuan Q; Kirikae T; Sasazuki T
    J Infect Dis; 2011 Jun; 203(11):1574-81. PubMed ID: 21592986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.
    Lu B; Tao L; Wang T; Zheng Z; Li B; Chen Z; Huang Y; Hu Q; Wang H
    Clin Vaccine Immunol; 2009 Jan; 16(1):73-7. PubMed ID: 18987164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine design for severe acute respiratory syndrome coronavirus.
    He Y; Jiang S
    Viral Immunol; 2005; 18(2):327-32. PubMed ID: 16035944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.
    Coughlin MM; Prabhakar BS
    Rev Med Virol; 2012 Jan; 22(1):2-17. PubMed ID: 21905149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models and vaccines for SARS-CoV infection.
    Roberts A; Lamirande EW; Vogel L; Jackson JP; Paddock CD; Guarner J; Zaki SR; Sheahan T; Baric R; Subbarao K
    Virus Res; 2008 Apr; 133(1):20-32. PubMed ID: 17499378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).
    Vogel LN; Roberts A; Paddock CD; Genrich GL; Lamirande EW; Kapadia SU; Rose JK; Zaki SR; Subbarao K
    Vaccine; 2007 Mar; 25(12):2173-9. PubMed ID: 17227689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
    Suresh MR; Bhatnagar PK; Das D
    J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.